Centinel Spine Secures $60M to Accelerate Global Innovation in Total Disc Replacement Technology

Centinel Spine®, LLC is proud to announce the successful closing of a $60,000,000 funding round that will further accelerate our mission to revolutionize spine care worldwide.

As the leading global medical device company focused on treating cervical and lumbar spinal diseases, we continue to build on our legacy of innovation with our industry-leading prodisc® total disc replacement (TDR) technology platform.

Backed by over 540 published papers and proven in more than 250,000 implantations around the globe, our prodisc system stands as the most clinically-proven TDR solution available, offering patients advanced, motion-preserving alternatives for both cervical and lumbar anterior column reconstruction.

This remarkable funding milestone not only underscores the confidence investors have in our pioneering approach but also provides the critical capital needed to expand our research and development efforts, accelerate further clinical studies, and enhance our product offerings.

The investment will support strategic initiatives that aim to broaden market access, refine our manufacturing capabilities, and strengthen our global distribution networks.

Our commitment to pushing the boundaries of spine surgery solutions is unwavering, and these funds will empower us to drive continuous innovation and improve patient outcomes internationally.

As we work towards reshaping the future of spine care, we invite stakeholders, healthcare professionals, and patients alike to join us in this transformative journey.

For more details about our groundbreaking technology and future innovations, please visit our website at www.CentinelSpine.com as we continue to be a catalyst of change in the spine industry.